Delta Asia International Corporation AI Stock Analysis
Delta Asia International Corporation (6762) AI Stock Analysis
Delta Asia International Corporation
(TPEx:6762)
The score is held back primarily by weak earnings quality and capital efficiency: despite 20% revenue growth, margins have compressed severely, net income is a fraction of 2020 levels, and return on equity has fallen below 2% while leverage remains elevated at roughly 1.05x debt-to-equity. Improving cash conversion — operating cash flow far exceeding net income and free cash flow turning positive — is the key offsetting strength. Technicals compound the caution, with the price below all major moving averages and negative MACD momentum, while a P/E above 300x and a minimal dividend yield leave valuation unattractive until the expanded asset base translates into restored profitability.
Delta Asia International Corporation (6762) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 5.54B
- Dividend Yield
- 0.34%
- Average Volume (3M)
- 4,411
- Price to Earnings (P/E)
- 326.8
- Beta (1Y)
- 0.17
- Revenue Growth
- -3.30%
- EPS Growth
- -69.37%
- Country
- TW
- Employees
- 220
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Delta Asia International Corporation Business Overview & Revenue Model
Company Description
Delta Asia International Corporation, headquartered in Taoyuan City, Taiwan, specializes in the production and distribution of both components and finished goods for the medical device industry. This Taiwanese firm commenced operations in 2004.
Delta Asia International Corporation Financial Statement Overview
Summary
Revenue grew about 20% to roughly NT$694 million, and cash generation improved materially — operating cash flow of about NT$218 million is roughly nine times reported net income, with free cash flow swinging positive to about NT$80 million after two heavy investment years. However, profitability has deteriorated sharply: gross margin fell from about 59% in 2020 to roughly 28%, net margin collapsed to 3.4%, and return on equity sits under 2%. Debt-funded expansion lifted debt-to-equity to 1.05x (down from 1.34x but far above the 0.40x of 2020–2022), leaving the enlarged asset base yet to prove it can earn an acceptable return.
Income Statement
44NeutralBalance Sheet
51NeutralCash Flow
56Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 678.17M | 694.15M | 580.51M | 508.02M | 462.97M | 531.32M |
| Gross Profit | 161.47M | 192.56M | 140.10M | 208.72M | 233.94M | 257.20M |
| EBITDA | 264.30M | 265.49M | 246.99M | 187.37M | 278.49M | 226.06M |
| Net Income | 17.57M | 23.43M | 57.19M | 85.78M | 171.30M | 130.25M |
Balance Sheet | ||||||
| Total Assets | 2.75B | 2.81B | 3.19B | 3.02B | 1.83B | 1.58B |
| Cash, Cash Equivalents and Short-Term Investments | 177.64M | 171.41M | 440.38M | 368.23M | 337.27M | 787.09M |
| Total Debt | 1.32B | 1.38B | 1.73B | 1.65B | 509.87M | 432.13M |
| Total Liabilities | 1.45B | 1.50B | 1.90B | 1.79B | 652.05M | 516.34M |
| Stockholders Equity | 1.30B | 1.31B | 1.29B | 1.24B | 1.18B | 1.07B |
Cash Flow | ||||||
| Free Cash Flow | 107.04M | 79.51M | -6.71M | -1.08B | -466.43M | 60.62M |
| Operating Cash Flow | 180.48M | 218.09M | 186.28M | 87.69M | 255.63M | 72.82M |
| Investing Cash Flow | -94.21M | -26.18M | -329.19M | -1.17B | -722.06M | -12.17M |
| Financing Cash Flow | -133.19M | -327.10M | 81.29M | 1.11B | 16.62M | -175.82M |
Delta Asia International Corporation Peers Comparison
Overall Rating
TW:416670Outperform
TW:412668Neutral
TW:474664Neutral
TW:178863Neutral
TW:416455Neutral- TW:676245Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4166 | 70Outperform | TWD 5.47B | 22.78 | ― | ― | ― | ― |
| TW:4126 | 68Neutral | TWD 5.39B | 12.54 | ― | 6.00% | 1.32% | 7.25% |
| TW:4746 | 64Neutral | TWD 5.43B | 11.42 | ― | 6.61% | -2.71% | ― |
| TW:1788 | 63Neutral | TWD 5.57B | 14.19 | ― | 5.56% | 7.58% | 13.04% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4164 | 55Neutral | TWD 4.79B | 21.84 | ― | 4.45% | 11.83% | 27.86% |
| TW:6762 | 45Neutral | TWD 5.43B | 326.79 | ― | 0.34% | -3.30% | -69.37% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6762 | Delta Asia International Corporation | 146.50 | -39.64 | -21.29% | |
| TW:1788 | Hi-Clearance Inc. | 126.00 | -4.42 | -3.39% | |
| TW:4126 | Pacific Hospital Supply Co., Ltd. | 75.00 | -8.60 | -10.29% | |
| TW:4164 | CHC Healthcare Group | 24.90 | -15.67 | -38.63% | |
| TW:4166 | Orient Pharma Co., Ltd. | 22.55 | -2.05 | -8.33% | |
| TW:4746 | Formosa Laboratories, Inc. | 45.40 | -15.89 | -25.92% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026